Analysts think TARA stock price could increase by 479%
Feb 11, 2025, 12:25 PM
-4.02%
What does TARA do
Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
6 analysts think TARA stock price will increase by 478.72%. The current median analyst target is $24.48 compared to a current stock price of $4.23. The lowest analysts target is $14.14 and the highest analyst target is $52.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
